Acadia Q2 net income $1.1M; DAYBUE launch strong with $23.2M sales; guides Q3 DAYBUE $45-55M

ACADIA PHARMACEUTICALS INC

2023-Q2 EPS reported -$0.26 revenue$165,235,000

Q2 net income of $1.1M ($0.01/share) vs net loss of $34.0M in prior year; total product sales $165.2M.
DAYBUE (trofinetide) first full quarter of sales: $23.2M; expanded licensing deal with Neuren for global rights.
NUPLAZID Q2 sales $142.0M, +5.5% YoY; full year guidance raised to $530-545M.
R&D expenses decreased to $58.8M; SG&A increased to $96.0M due to DAYBUE launch costs.
Appointed Dr. Kevin R. Oliver as SVP, Chief Business Officer; Phase 3 negative symptoms schizophrenia trial enrollment complete, results Q1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ACADIA PHARMACEUTICALS INC reported the six months ended June 30, 2023 results: revenue $283.7 million, net income a net loss of $41.9 million, or $0.26 per common share, EPS $0.26 per common share.

Period: the six months ended June 30, 2023
Revenue: $283.7 million
Net income: a net loss of $41.9 million, or $0.26 per common share
EPS: $0.26 per common share
Result: reported results

Exact text from the filing

Total net product sales, comprised of NUPLAZID and DAYBUE were $165.2 million for the three months ended June 30, 2023, and were $283.7 million for the six months ended June 30, 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ACADIA PHARMACEUTICALS INC reported the second quarter ended June 30, 2023 results: revenue $165.2 million, net income $1.1 million, or $0.01 per common share, EPS $0.01 per common share.

Period: the second quarter ended June 30, 2023
Revenue: $165.2 million
Net income: $1.1 million, or $0.01 per common share
EPS: $0.01 per common share
Result: reported results

Exact text from the filing

Total net product sales, comprised of NUPLAZID and DAYBUE were $165.2 million for the three months ended June 30, 2023

View on SEC.gov

Browse all earnings releases →

ACADIA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-037216

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.